OREX - Orexigen Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.2229
-0.1170 (-34.42%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3399
Open0.2449
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2200 - 0.3198
52 Week Range0.1700 - 3.1300
Volume3,735,420
Avg. Volume1,827,448
Market Cap4.21M
Beta1.60
PE Ratio (TTM)N/A
EPS (TTM)-9.6580
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • The Wall Street Journal14 days ago

    [$$] Firm Retention Summary: Orexigen Therapeutics Inc.

    This is a summary of a request from the official committee of unsecured creditors of Orexigen Therapeutics Inc. to hire Irell & Manella LLP as counsel, filed April 27 with the U.S. Bankruptcy Court in ...

  • The Wall Street Journallast month

    [$$] Pernix, Investor Group Offer $75 Million for Orexigen

    The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.

  • PR Newswirelast month

    Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company

    SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval.  Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.

  • The Wall Street Journallast month

    [$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors

    Drugmaker’s sale targets are too easy to hit, creditors committee says

  • The Wall Street Journal2 months ago

    [$$] Firm Retention Summary: Orexigen Therapeutics Inc.

    This is a summary of a request from Orexigen Therapeutics Inc. to hire Morris Nichols Arsht & Tunnell LLP as Delaware bankruptcy co-counsel, filed March 23 with the U.S. Bankruptcy Court in Wilmington, ...

  • This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy
    Motley Fool2 months ago

    This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy

    It's all about the pipeline.

  • Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?
    Simply Wall St.2 months ago

    Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?

    Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last fewRead More...

  • 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
    Insider Monkey2 months ago

    30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets

    The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]

  • Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
    Zacks2 months ago

    Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy

    The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.

  • Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
    Zacks2 months ago

    Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code

    Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.

  • The Wall Street Journal2 months ago

    [$$] Orexigen to Use Some Bankruptcy Financing on Advertising

    A bankruptcy judge approved $35 million in new loans for drugmaker Orexigen Therapeutics, which said it would use some of the money to advertise its anti-obesity drug, Contrave.

  • The Wall Street Journal2 months ago

    Orexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss Drugs

    Drugmaker Orexigen filed for bankruptcy protection on Monday and plans to sell itself, after failing to find a profitable market for its weight-loss treatment Contrave.

  • The Wall Street Journal2 months ago

    [$$] Orexigen Plans to Sell Itself Through Chapter 11 Bankruptcy

    Biopharmaceutical company Orexigen Therapeutics plans to sell itself later this year through bankruptcy proceedings.

  • Reuters2 months ago

    US STOCKS-Wall Street set to open higher as inflation worries ease

    U.S. stock index futures pointed to a higher opening for Wall Street on Monday, building on gains from last week's strong February jobs data that allayed fears of rising inflation and faster interest rate hikes. Wall Street's main indexes closed up nearly 2 percent on Friday after data showed U.S. job additions in February grew by a strong clip but wage growth was sluggish. Traders of U.S. short-term interest-rate futures kept bets the Federal Reserve will stick to three rate hikes this year.

  • Reuters2 months ago

    U.S. drugmaker Orexigen files for Chapter 11 bankruptcy

    Drugmaker Orexigen Therapeutics Inc said on Monday it filed for Chapter 11 bankruptcy protection and will also file a motion to pursue an auction and sale process of substantially all its assets. The company, which focuses on the treatment of obesity, said it expects proposed bids to be submitted by May 21 and the sale is intended to be concluded by July 2. Orexigen listed assets in the range of $50 million to $100 million and liabilities in the range of $100 million to $500 million, according to a filing in the Delaware bankruptcy court.

  • PR Newswire2 months ago

    Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code

    SAN DIEGO, March 12, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Orexigen also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers to acquire substantially all of Orexigen's assets, which would be purchased free and clear of the company's indebtedness and other liens and interests.

  • Why Orexigen Therapeutics Inc’s (NASDAQ:OREX) Ownership Structure Is Important
    Simply Wall St.4 months ago

    Why Orexigen Therapeutics Inc’s (NASDAQ:OREX) Ownership Structure Is Important

    In this article, I’m going to take a look at Orexigen Therapeutics Inc’s (NASDAQ:OREX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Orexigen Struggles as Contrave Commercialization Costs Rise
    Zacks5 months ago

    Orexigen Struggles as Contrave Commercialization Costs Rise

    Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

  • Capital Cube5 months ago

    ETFs with exposure to Orexigen Therapeutics, Inc. : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Orexigen Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OREX-US. Comparing the performance and risk of Orexigen Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
    Capital Cube5 months ago

    Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Orexigen Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Orexigen Therapeutics, Inc. – Arena Pharmaceuticals, Inc., VIVUS, Inc., Zafgen, Inc. and Lannett Company, Inc. (ARNA-US, VVUS-US, ZFGN-US and LCI-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • Implied Volatility Surging for Orexigen (OREX) Stock Options
    Zacks5 months ago

    Implied Volatility Surging for Orexigen (OREX) Stock Options

    Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.

  • Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?
    Simply Wall St.6 months ago

    Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?

    Orexigen Therapeutics Inc (NASDAQ:OREX), a USD$27.89M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of OREX earnings conference call or presentation 13-Nov-17 10:00pm GMT

    Q3 2017 Orexigen Therapeutics Inc Earnings Call

  • What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?
    Simply Wall St.6 months ago

    What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?

    Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...

  • Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up
    Zacks6 months ago

    Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

    Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.